retatrutide phase 3 Lilly's triple agonist delivers up to 71.2 lbs of weight loss Retatrutide Phase 3: TRIUMPH Program

Discuss GLP-1 and GIP treatment options, including Tirzepatide, Semaglutide, Mounjaro, Zepbound, Wegovy, and Ozempic for eligible patients

Services Pricing Upfront pricing.No memberships.No hidden fees

The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate

This study aimed to determine its role in mitigating diet-induced metabolic disorders, such as obesity, insulin resistance, and fatty liver disease, in ...

Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)

Learn what the evidence shows about muscle symptoms with semaglutide, tirzepatide, and other GLP-1 medications, plus when to contact your doctor and how to protect muscle mass during treatment.